Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Cholesteryl ester transfer protein (CETP) facilitates lipid exchange between lipoproteins.
• Initially, CETP inhibitors aimed to increase HDL cholesterol (HDL-C) for atherosclerotic cardiovascular disease (ASCVD) risk reduction.
• Emerging evidence supports CETP inhibition for lowering atherogenic lipoproteins like LDL-C and apoB.

Purpose of the Study:

• To review the current understanding of CETP inhibition.
• To examine the relationship between CETP inhibition and ASCVD risk reduction.
• To highlight the shift in therapeutic focus from HDL-C elevation to apoB reduction.

Main Methods:

• Review of animal models, observational studies, randomized controlled trials, and Mendelian randomization studies.
• Analysis of cardiovascular outcome trial data for CETP inhibitors like anacetrapib.
• Examination of data on newer CETP inhibitors such as obicetrapib.

Main Results:

• Anacetrapib trials demonstrated significant reduction in major coronary events, proportional to LDL-C and apoB lowering.
• Pharmacologic CETP inhibition is effective in reducing LDL-C, non-HDL-C, and apoB concentrations.
• Obicetrapib shows substantial LDL-C and apoB reduction when combined with high-intensity statins.

Conclusions:

• CETP inhibition's primary benefit in ASCVD risk reduction is now attributed to lowering apoB-containing lipoproteins.
• CETP inhibitors represent a promising therapeutic strategy for managing ASCVD.
• Ongoing trials will further elucidate the role of CETP inhibition in cardiovascular event reduction.